ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for alerts 登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ARGX Argen X SE

350.80
2.30 (0.66%)
2024年5月1日 - 終了
15分遅延
名称 銘柄コード 市場 種別
Argen X SE ARGX ユーロネクスト Ordinary Share
  前日比 前日比 % 現在値 時刻
2.30 0.66% 350.80 00:40:00
始値 安値 高値 終値 前日終値
349.20 347.20 354.50 350.80 348.50
この銘柄の詳細情報 »

最新ニュース

日付 時間 ソース タイトル
2024/4/1614:00GLOBEargenx Data Highlight Evidence that VYVGART and VYVGART..
2024/3/2715:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
2024/3/2705:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
2024/3/2615:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
2024/3/0806:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
2024/2/2915:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
2024/2/2615:00GLOBEargenx to Present at Upcoming Investor Conferences
2024/2/2215:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
2024/2/2015:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
2024/1/1815:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
2024/1/0815:00GLOBEargenx Highlights 2024 Strategic Priorities
2024/1/0215:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
2023/12/2015:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
2023/11/2815:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
2023/11/1621:40GLOBEargenx Announces European Commission Approval of..
2023/11/0115:00GLOBEargenx Highlights Data Evaluating VYVGART in Neuromuscular..
2023/10/3115:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
2023/10/2414:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
2023/9/2114:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
2023/9/1514:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
2023/8/3014:00GLOBEargenx to Present at Upcoming Investor Conferences
2023/7/2714:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
2023/7/2505:30GLOBEargenx announces closing of global offering
2023/7/2014:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
2023/7/2006:58GLOBEargenx announces full exercise of underwriters’ option to..
2023/7/1910:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
2023/7/1805:01GLOBEargenx announces launch of proposed global offering
2023/7/1714:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
2023/6/3022:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
2023/6/2107:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
2023/6/2014:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
2023/5/3114:00GLOBEargenx to Present at Upcoming Investor Conferences
2023/5/0414:00GLOBEargenx Reports First Quarter 2023 Financial Results and..
2023/5/0405:01GLOBEargenx announces results of Annual General Meeting of..

最近閲覧した銘柄

Delayed Upgrade Clock